News Release

Patients at risk for complications after coronary artery fistula closure

American Heart Association journal news

Peer-Reviewed Publication

American Heart Association

Long-term complications after procedures to close coronary artery fistulas are particularly prevalent among those whose abnormal connections to the heart result in drainage into the coronary sinus, according to a study published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association.

A coronary artery fistula is an abnormal connection between a coronary artery and a chamber of the heart or vessel. The coronary sinus is the end portion of a large vein at the back of the heart that receives blood from the heart's veins and empties into the right atrium.

The study found that procedures to close a CAF were associated with increased long-term risks of angina, coronary thrombosis (a clot in one of the heart's blood vessels), heart failure and heart attack.

To determine which patients are most at risk for these complications after closure, researchers reviewed the medical records of 76 patients diagnosed with congenital coronary artery fistula. Sixty-four patients underwent transcatheter closure or surgical repair of the fistula.

The researchers found that 15 percent of patients had major complications following closure, including heart attack, angina with coronary thrombosis, or symptomatic cardiomyopathy (heart failure). The only angiographic finding associated with major complications was drainage of the coronary artery fistula into the coronary sinus.

Other predictors associated with adverse outcomes included older age at diagnosis, tobacco use, diabetes, hypertension and hyperlipidemia (or high cholesterol).

Physicians should consider reducing atherosclerotic risk factors and long-term use of blood thinning medications after coronary artery fistula closure, especially for patients with fistula that drain into the coronary sinus, the researchers said.

###

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

NR10 – 1051 (Circ Interventions/Valente)


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.